Generation of cDC-like cells from human induced pluripotent stem cells via Notch signaling

Kenichi Makino1,2, Mark D Long3, Ryutaro Kajihara1

  • 1Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Insights

Generating functional dendritic cells (DCs) from human induced pluripotent stem cells (iPSCs) is now possible. Notch signaling is critical for developing these iPSC-derived DCs for cancer immunotherapy.

Area of Science:

  • Immunology
  • Stem Cell Biology
  • Cancer Research

Background:

  • Dendritic cells (DCs) are crucial for immune responses and cancer immunotherapy.
  • Conventional type 1 DCs (cDC1s) are effective in inducing antitumor immunity but difficult to obtain in large numbers.
  • Generating cDC1s from human induced pluripotent stem cells (iPSCs) has been a significant challenge.

Purpose of the Study:

  • To investigate the generation of dendritic cells (DCs) from human induced pluripotent stem cells (iPSCs).
  • To elucidate the role of Notch signaling in the differentiation of iPSC-derived DCs.
  • To establish a method for producing large quantities of autologous DCs for therapeutic applications.

Main Methods:

  • Human iPSCs were differentiated into myeloid cells in vitro using feeder-dependent and feeder-free systems.
  • Phenotypic, genomic, and transcriptomic analyses were performed on iPSC-derived DCs.
  • Notch signaling was manipulated using gain- and loss-of-function approaches to study its impact on DC differentiation.

Main Results:

  • iPSCs successfully differentiated into various DC subsets, including cDC1s (CD141+XCR1+CLEC9A+), on OP9-DL1 feeder cells.
  • Notch signaling inhibition abrogated the generation of cDC1s and other DC subsets, while increasing DC3s.
  • iPSC-derived cDC1s exhibited gene expression profiles similar to peripheral blood cDC1s and possessed key immunological functions.

Conclusions:

  • Notch signaling plays a critical role in regulating the developmental pathways of human cDCs from iPSCs.
  • This study provides a foundation for developing personalized cancer immunotherapies using iPSC-derived DCs.
  • The ability to generate unlimited autologous DCs from iPSCs holds promise for repeated vaccination strategies.
Abstract